A Multipart, Open-label Study to Evaluate the Safety and Efficacy of ABT-450/r/ABT-267 With and Without ABT-333 Coadministered With and Without Ribavirin in Adult With Genotype 1 or 4 Hepatitis C Virus (HCV) Infection and Human Immunodeficiency Virus, Type 1 Coinfection

Percentage of Participants in Part 1a Achieving SVR12

SVR12 is defined as plasma HCV RNA \< LLOQ 12 weeks after the last dose of study drug without any confirmed quantifiable (≥ LLOQ) post-treatment value before or during that SVR window. The 95% CI is calculated using the Wilson score method for binomial distribution.

Time frame: 12 weeks after last dose of study drug

Percentage of Participants in Part 1b Achieving SVR12

SVR12 is defined as plasma HCV RNA \< LLOQ 12 weeks after the last dose of study drug without any confirmed quantifiable (≥ LLOQ) post-treatment value before or during that SVR window. The 95% CI is calculated using the Wilson score method for binomial distribution.

Time frame: 12 weeks after last dose of study drug

Percentage of Participants in Arm F and Arm G of Part 2 Achieving SVR12

SVR12 is defined as plasma HCV RNA \< LLOQ 12 weeks after the last dose of study drug without any confirmed quantifiable (≥ LLOQ) post-treatment value before or during that SVR window. The 95% CI is calculated using the Wilson score method for binomial distribution.

Time frame: 12 weeks after last dose of study drug

Percentage of Participants With GT4 HCV in Part 2 Achieving SVR12, by Arm and Overall

SVR12 is defined as plasma HCV RNA \< LLOQ 12 weeks after the last dose of study drug without any confirmed quantifiable (≥ LLOQ) post-treatment value before or during that SVR window. The 95% CI is calculated using the Wilson score method for binomial distribution.

Time frame: 12 weeks after last dose of study drug

Percentage of Participants in Part 1a With On-Treatment HCV Virologic Failure During the Treatment Period

Percentage of participants with on-treatment HCV virologic failure during the treatment period for each arm in Part 1a. Virologic failure is defined as confirmed quantifiable HCV RNA among participants with previously unquantifiable HCV RNA during treatment.

Time frame: up to 12 or 24 weeks, based on treatment duration

Percentage of Participants in Part 1b With On-Treatment HCV Virologic Failure During the Treatment Period

Percentage of participants with on-treatment HCV virologic failure during the treatment period for each arm and overall in Part 1b. Virologic failure is defined as confirmed quantifiable HCV RNA among participants with previously unquantifiable HCV RNA during treatment.

Time frame: up to 12 weeks

Percentage of Participants in Part 2 With On-Treatment HCV Virologic Failure During the Treatment Period

Percentage of participants with on-treatment HCV virologic failure during the treatment period for arms in Part 2. Virologic failure is defined as confirmed quantifiable HCV RNA among participants with previously unquantifiable HCV RNA during treatment.

Time frame: up to 12 or 24 weeks, based on treatment duration

Percentage of Participants in Part 1a With Relapse12

Percentage of participants who experienced Relapse12 among participants who completed treatment with HCV RNA \< LLOQ at final treatment visit and had at least one post-treatment HCV RNA value. Relapse12 is defined as confirmed HCV RNA ≥ LLOQ between end of treatment and 12 weeks after last actual dose of study drug (up to and including the SVR12 assessment time point) for a participant with HCV RNA \< LLOQ at final treatment visit who completed treatment and had post-treatment data. Completion of treatment is defined as study drug duration ≥ 77 days for Arm A and ≥ 154 days for Arm B. The 95% CI is calculated using Wilson score method for the binomial distribution.

Time frame: up to 12 or 24 weeks, based on treatment duration, after the last actual dose of study drug

Percentage of Participants in Part 1b With Relapse12 for Each Arm and Overall

Percentage of participants who experienced Relapse12 among participants who completed treatment with HCV RNA \< LLOQ at final treatment visit and had at least one post-treatment HCV RNA value. Relapse12 is defined as confirmed HCV RNA ≥ LLOQ between end of treatment and 12 weeks after last actual dose of study drug (up to and including the SVR12 assessment time point) for a participant with HCV RNA \< LLOQ at final treatment visit who completed treatment and had post-treatment data. Completion of treatment is defined as study drug duration ≥ 77 days for Arm C and Arm D. The 95% CI is calculated using Wilson score method for the binomial distribution.

Time frame: up to 12 weeks after the last actual dose of study drug

Percentage of Participants in Part 2 With Relapse12

Percentage of participants who experienced Relapse12 among those who completed treatment with HCV RNA \< LLOQ at final treatment visit and had ≥1 post-treatment HCV RNA value. Relapse12=confirmed HCV RNA ≥ LLOQ between end of treatment and 12 weeks after last actual dose of study drug (up to and including the SVR12 window) for a participant with HCV RNA \< LLOQ at final treatment visit who completed treatment and had post-treatment data, excluding reinfection. Completion of treatment=study drug duration ≥ 77 days for participants who received 12 weeks of treatment and ≥154 days for participants who received 24 weeks of treatment. HCV reinfection=confirmed HCV RNA ≥ LLOQ after the end of treatment in a subject who had HCV RNA \< LLOQ at final treatment visit, along with the post-treatment detection of a different HCV genotype, subtype, or clade compared with baseline, as determined by phylogenetic analysis. The 95% CI is calculated using Wilson score method for the binomial distribution.

Time frame: up to 12 or 24 weeks, based on treatment duration, after the last actual dose of study drug

Percentage of Participants in Part 1a With Plasma HIV-1 RNA Suppression at End of Treatment and 12 Weeks Post-Treatment

HIV virologic success was defined as HIV-1 RNA suppression (HIV-1 RNA value \< 40 copies/mL).

Time frame: End of treatment: HIV Week 12 window for 12-weeks of treatment (Treatment Day 71 - 98) or HIV Week 24 window (Treatment Day 155 - 182) for 24-weeks of treatment. Post-Treatment Week 12 (PTW12): HIV PTW12 window (Post-Treatment Day 57 - 126)

Percentage of Participants in Part 1b With Plasma HIV-1 RNA Suppression at End of Treatment and 12 Weeks Post-Treatment

HIV virologic success was defined as HIV-1 RNA suppression (HIV-1 RNA value \< 40 copies/mL).

Time frame: End of treatment: HIV Week 12 window (Treatment Day 78 - 98). PTW12: HIV PTW12 window (Post-Treatment Day 57 - 126)

Percentage of Participants in Part 2 With Plasma HIV-1 RNA Suppression at End of Treatment and 12 Weeks Post-Treatment

HIV virologic success was defined as HIV-1 RNA suppression (HIV-1 RNA value \< 40 copies/mL).

Time frame: End of treatment: HIV Week 12 window for 12-weeks of treatment (Treatment Day 71 - 98) or HIV Week 24 window (Treatment Day 155 - 182) for 24-weeks of treatment. PTW12: HIV PTW12 window (Post-Treatment Day 57 - 126)